CN102268753A - Manufacturing method of polymer fiber and wound dressing and obtained wound dressing - Google Patents

Abstract

The invention provides a method for manufacturing polymer fibers and a wound dressing and the obtained wound dressing. The method for producing a polymer fiber comprises: carrying out wet spinning on an aqueous spinning solution containing a natural polymer material and a spinning forming solution to form wet polymer precursor; immersing the wet-type polymer precursor into a softening agent to obtain the wet-type polymer precursor treated by the softening agent; and immersing the wet polymer precursor treated by the softening agent into a volatile solvent to remove water in the polymer precursor to form polymer fibers. The invention also provides a method for preparing the wound dressing by using the obtained polymer fiber and the obtained wound dressing, wherein the obtained polymer fiber is formed into a polymer fiber non-woven fabric; and treating the non-woven fabric with a natural polymer solution to form a porous coating on polymer fibers of the non-woven fabric to obtain the wound dressing. By the method of the invention, the manufacturing time of the wound dressing can be shortened and the energy consumption required for drying can be reduced.

Description

Manufacturing method of polymer fiber and wound dressing and obtained wound dressing

technical field

The present invention relates to a method for producing polymer fibers and a method for producing wound dressings composed of polymer fibers. The invention also relates to wound dressings produced by the method of the invention.

Background technique

Most of the currently used wound dressings are based on hydrogel, film or sponge-like structural materials. Although these dressings have been used in the market for a considerable period of time, the application of these materials has been limited due to issues such as mechanical strength, liquid absorption capacity and liquid absorption speed. According to the research of past scholars, the most common three-dimensional configurations are sponge and non-woven fabrics, and the permeability and water absorption of non-woven fabrics are better than those of sponges. Moreover, the non-woven configuration has a better three-dimensional structure, so that cells can have better space adsorption and cell proliferation functions. In addition, the non-woven fabric configuration has good softness and certain mechanical strength, and its manufacturing cost can be reduced through the continuous manufacturing method of textile technology, and a medical-grade dressing material with high quality and low price can be produced.

Common wound dressings are made of natural regenerated polymer fibers. Wound dressings are generally made by wet spinning technology, and the fibers are dried using freeze drying technology. However, the freeze-drying manufacturing method is time-consuming and energy-consuming; and in the non-woven fabric manufacturing method, if the hydroforming technology is used, another time-consuming and energy-consuming freeze-drying manufacturing method is required, while the needle-punching technology requires additional needles. machine equipment. Therefore, the traditional method of manufacturing natural regenerated polymer fibers or non-woven fibers as wound dressings is time-consuming and requires expensive equipment.

Contents of the invention

In order to overcome the problems of the fiber or non-woven fabric used in the manufacture of wound dressings in the prior art, the present invention provides a method for manufacturing wound dressings, which replaces freeze-drying with different drying methods, which not only shortens the time of the manufacturing method but also reduces energy consumption. consume.

Therefore, at first the present invention provides a kind of manufacture method of polymer fiber, it is characterized in that comprising the following steps:

(i) wet-spinning an aqueous spinning dope (aqueous dope) containing a natural polymer material and a spinning forming liquid to form a wet polymer precursor;

(ii) immersing the wet polymer precursor in a softener to obtain a softener-treated wet polymer precursor;

(iii) immersing the softener-treated wet polymer precursors in a volatile solvent to remove moisture from the polymer precursors to form polymer fibers.

In a specific embodiment, the natural polymer material is chitosan, alginate or a combination thereof.

In a specific embodiment, the aqueous spinning dope containing natural polymer materials is a chitosan solution with a concentration of 3 to 10% by weight (w/w%), and the spinning forming solution contains at least an alkaline compound , and its concentration is 3 to 10% by weight.

In a specific embodiment, the aqueous spinning stock solution containing natural polymer materials is a sodium alginate solution with a concentration of 3 to 10% by weight; and the spinning forming solution contains divalent cations at a concentration of 3 to 10% by weight %.

In a specific embodiment, the softening agent is a glycerin solution with a concentration of 0.1 to 25% by weight or a solution of polysorbate with a concentration of 0.1 to 10% by weight.

In a specific embodiment, the volatile solvent is a lower carbon number alcohol, a lower carbon number ketone or a lower carbon number ether.

The present invention also provides a manufacturing method of a wound dressing, which is characterized in that it comprises the following steps:

(i) obtain high molecular fiber with aforementioned method;

(ii) forming the polymer fiber into a polymer fiber non-woven fabric; and

(iii) treating the non-woven fabric with a natural polymer solution to form a porous coating on the polymer fibers of the non-woven fabric, thereby obtaining a wound dressing.

In a specific embodiment, the step of treating the polymer fiber non-woven fabric with the natural polymer solution includes: spraying the natural polymer onto the non-woven fabric to form a non-woven fabric with a porous coating on the polymer fiber; The layers of nonwoven fabric are dried to obtain a wound dressing. Preferably, the natural polymer is sprayed onto the non-woven fabric at a spray rate of 10 to 100 milliliters per minute. And preferably, the drying of the nonwoven fabric with the porous coating is carried out at a temperature of 35 to 85°C.

In a preferred embodiment, the natural polymer solution is selected from the group consisting of sodium alginate, collagen, gelatin, hyaluronic acid, chitosan, derivatives and mixtures thereof.

In another aspect, the present invention also provides a wound dressing produced by the method according to the present invention. Specifically, the wound dressing manufactured by the method of the present invention will contain a non-woven mesh with polymer fibers; and a porous coating formed on the polymer fibers in the non-woven mesh.

According to the method of the invention, wound dressings can be mass-produced without complicated drying steps. Therefore, the method according to the invention and the wound dressing obtained by this method are of great economic value. And the wound dressing obtained according to the method of the present invention has improved wound healing and blood coagulation effects without causing animal irritation.

Description of drawings

Figure 1 is a comparison of the coagulation test results of the commercially available dressing and the dressing of the comparative example.

Fig. 2 is a comparison of the coagulation test results of the dressing obtained by the method of the present invention and the dressing of the comparative example.

Detailed ways

A kind of manufacture method of polymer fiber is characterized in that comprising the following steps:

(i) wet-spinning the water-based spinning stock solution containing the natural polymer material and the spinning forming solution to form a wet polymer precursor;

(ii) immersing the wet polymer precursor in a softener to obtain a softener-treated wet polymer precursor;

(iii) immersing the softener-treated wet polymer precursors in a volatile solvent to remove moisture from the polymer precursors to form polymer fibers.

A kind of manufacture method of wound dressing is characterized in that comprising the following steps:

(i) obtain polymer fiber according to the method for claim 1;

(ii) forming the polymer fiber into a polymer fiber non-woven fabric; and

(iii) treating the non-woven fabric with a natural polymer solution to form a porous coating on the polymer fibers of the non-woven fabric, thereby obtaining a wound dressing.

According to the present invention, the step of forming a nonwoven of polymeric fibers includes any method known in the art for making a nonwoven from fibers of appropriate length. For example, the nonwoven fabric with the polymer fibers can be formed by carding and hydrolaid.

In a preferred specific embodiment, the step of forming the polymer fiber nonwoven fabric includes: carding the polymer fiber to obtain a polymer fiber clump.

In a preferred embodiment, the polymer fibers are evenly dispersed on a collecting roller, followed by polymer fiber bonding.

In a preferred specific embodiment, the step of forming the polymer fiber non-woven fabric includes: cutting the polymer fiber into short fibers and then laying them in water to form a wet-laid non-woven fabric.

According to the present invention, the natural polymer material can be chitosan, alginate or a combination thereof.

In a preferred embodiment of the present invention, the aqueous spinning stock solution containing the natural polymer material is a chitosan solution with a concentration of 3 to 10% by weight; and the spinning forming solution contains at least an alkaline compound at a concentration of 3 to 10% by weight.

In another preferred embodiment of the present invention, the aqueous spinning stock solution containing natural polymer materials is a sodium alginate solution with a concentration of 3 to 10% by weight; and the spinning forming solution contains divalent cations at a concentration of 3 to 10% by weight.

According to the present invention, the divalent cations include but are not limited to calcium ions.

According to the present invention, the softening agent can keep the wet-laid polymer precursors with proper softness.

According to the present invention, softening agents include but are not limited to glycerin, polysorbate and derivatives thereof, for example, Tween-20 (Tween-20), Tween-60, Tween-80 and Span-80 (Span-80). 80). Preferably, the softening agent is a solution of glycerol with a concentration of 0.1 to 25% by weight or a solution of polysorbate with a concentration of 0.1 to 10% by weight.

According to the present invention, the wet polymer precursor treated with the softening agent is immersed in a volatile solvent. The volatile solvent is preferably low carbon number alcohols, low carbon number ketones or low carbon number ethers.

The low carbon number alcohols can be methanol, ethanol, propanol, butanol, pentanol, hexanol. The low carbon number ketones can be C ₁ to C ₆ ketones. The lower carbon number ethers can be C ₂ to C ₆ ethers.

In a preferred embodiment of the present invention, the step of treating the non-woven fabric with a natural polymer solution is to increase the bonding effect between fibers, which includes:

Spraying the natural polymer solution onto the non-woven fabric to form a non-woven fabric with a porous coating on the polymer fibers; and

The nonwoven fabric with the porous coating is dried to obtain a wound dressing.

Preferably, the natural polymer solution is sprayed onto the non-woven fabric at a spray rate of 10 to 100 milliliters per minute.

Preferably, drying of the nonwoven with a porous coating is carried out at a temperature of 35 to 85° C. to obtain a wound dressing.

According to the present invention, the natural polymer solution contains at least one of the following: sodium alginate, collagen, gelatin, hyaluronic acid, chitosan, derivatives and mixtures thereof.

According to the above description, a wound dressing prepared according to the method of the present invention will comprise a non-woven mesh with polymer fibers; and a porous coating formed on the polymer fibers in the non-woven mesh.

The term "polymer fiber non-woven fabric network body" used herein refers to a fabric made from polymer fibers produced by the method of the present invention, using any method known in the art for preparing non-woven fabrics.

The technical means adopted by the present invention to achieve the purpose of the invention and the related experimental results are further described below through the embodiments of the present invention.

Comparative Example: Manufacturing Chitosan Composite Fibers with Prior Art

Formulate an alkaline forming liquid containing at least an alkaline compound. A 5% by weight chitosan solution was prepared and extruded into the above-mentioned molding solution for wet spinning to form wet chitosan spinning. Wet chitosan spinning was followed by freeze-drying to obtain chitosan fibers. Take a certain amount of chitosan fibers, cut them into 2 to 3 cm lengths, disperse them in water, and disperse them with a high-speed stirring disperser, then form chitosan fiber non-woven fabrics by water scooping, and finally freeze-dry Remove moisture. In this comparative example, two freeze-drying manufacturing methods were used successively, each of which took 2 to 3 days for freeze-drying, the manufacturing time was lengthy, and a large amount of electricity was required for the operation of the freeze-drying machine.

Embodiment 1: manufacture chitosan composite fiber with the method of the present invention

A 5% by weight solution of chitosan (molecular weight about 300k Dalton) was prepared. An alkaline forming liquid containing at least 5% by weight of sodium hydroxide is prepared. The chitosan solution is extruded into the above-mentioned forming liquid for molding, and wet spinning is performed to form wet chitosan spinning. Soak the obtained wet chitosan spinning in 2 vol% Tween-20 for 5 minutes, then immerse in 50 vol%, 60 vol%, and 70 vol% ethanol for 5 minutes each for solvent replacement, then The excess solvent was removed by a suction machine, and then dried in an oven at 60° C. for 2 hours to obtain chitosan composite fibers. The total production time is 4 hours.

Embodiment 2: manufacture sodium alginate composite fiber with the inventive method

A 5% by weight sodium alginate solution was prepared. Prepare a molding solution containing 5% calcium chloride. The sodium alginate solution is extruded into the above-mentioned forming solution for molding, and wet spinning is performed to form wet sodium alginate spinning. Soak the obtained wet sodium alginate spinning in 2 vol% Tween-20 for 5 minutes, then soak in 50 vol%, 60 vol%, and 70 vol% ethanol for 5 minutes each for solvent replacement, then use The excess solvent was removed by a suction machine, and then dried in an oven at 60° C. for 2 hours to obtain sodium alginate composite fibers. The total production time is 4 hours.

Example 3: Preparation of Composite Wound Dressing Using Porous Biomacromolecule Materials

Cut the chitosan composite fiber obtained in Example 1 into short fibers of appropriate length, and process the fiber with a carding machine, while spraying 0.5% alginic acid on the chitosan composite fiber cotton web on the take-up roller The sodium solution is sprayed at a rate of 50 milliliters per minute per unit time for fiber bonding, followed by drying to form a porous biopolymer material containing sodium alginate. When performing this step, the sodium alginate solution can be replaced with various biopolymer solutions, such as collagen, gelatin, hyaluronic acid, etc., to form various porous biopolymer materials.

Then, the obtained porous biopolymer material was removed with a suction machine to remove excess water, and then dried in an oven at 60° C. for 2 hours, and finally a wound dressing with both non-woven and porous composite forms was obtained. This chitosan composite wound dressing was used in the following examples.

Example 4: Basis Weight Test of Composite Wound Dressings

The obtained chitosan composite wound dressing was cut into a square with a size of 10cm×10cm, the weight was measured with an electronic balance, and the results of nine samples were recorded and averaged. The measurement results are shown in Table 1. After calculation, the average basis weight of the nonwoven fabric is 0.0146g/cm ² , and the basis weight after unit conversion is 146g/m ² .

Table 1 Basis weight test results of chitosan composite wound dressing (100cm ² )

Embodiment 5: liquid absorption test of composite wound dressing

1. Experimental materials and equipment:

A. the chitosan composite wound dressing obtained by the method of embodiment 3;

b. Deionized water and different concentrations of physiological saline.

2. Experimental method:

a. Take a composite wound dressing of a certain size and measure the weight on an electronic balance.

b. Soak the weighted composite wound dressings in physiological saline of different concentrations as indicated below for about 8 hours.

c. Take out the composite wound dressing swollen due to immersion in saline, and measure the weight after fluid absorption with an electronic balance.

d. Calculate the weight difference before and after immersion and the value of the degree of liquid absorption.

The calculation results are shown in Table 2. It can be seen from Table 2 that under the treatment of different concentrations of physiological saline solution, the liquid absorption rate is greater than 100%, and the liquid absorption rate will decrease with the increase of the concentration of the physiological saline solution used.

Table 2 Liquid absorption test results

Solution concentration (%) 0 0.25 0.5 1 Liquid absorption rate (%) 707.79 522.03 439.77 402.29

Example 6: Coagulation Test of Composite Wound Dressings

1. Experimental materials and equipment:

A. the chitosan composite wound dressing obtained by the method of embodiment 3;

B. the chitosan wound dressing that obtains with comparative example method;

c. Physiological saline;

d. Volunteer whole blood;

e. ELISA (BioAssay Systems QuantiChromTM Hemoglobin Assaykit);

，ConvaTec，USA)作为本实验的控制组。f. Commercially available wound dressing (trade name Kaltostat

, ConvaTec, USA) was used as the control group in this experiment.

2. Experimental method:

a. Extract venous whole blood from volunteers, open the cover, shake and oxygenate for 30 minutes;

b. Mix 0.1 g of chitosan wound dressing with 30 μL of blood, and after mixing for 30, 60, 90 and 120 seconds, take out the dressing and shake it in normal saline for 4 minutes;

c. Take out the supernatant and measure the absorbance value at 540nm by ELISA, the reference wavelength is 650nm.

、市售以针轧技术制造的敷料与比较实施例以湿式纺丝制造的创伤敷料的凝血效果比较，比较实施例与市售敷料具有相似的效果。菱形和方形表示市售敷料的结果，三角形表示比较实施例中以湿式纺丝制造的创伤敷料的结果。由图可见，比较实施例使用湿式纺丝获得敷料的凝血效果和市售以针轧技术获得的敷料效果相似。The results of the ELISA experiment are shown in Figure 1 and Figure 2. Figure 1 shows the commercially available dressing Kaltostat

1. Comparing the blood coagulation effect of the commercially available dressing made by needle rolling technology and the wound dressing made by wet spinning in the comparative example, the comparative example and the commercially available dressing have similar effects. The diamonds and squares represent the results for commercially available dressings, and the triangles represent the results for the wound dressings produced by wet spinning in Comparative Examples. It can be seen from the figure that the coagulation effect of the dressing obtained by wet spinning in Comparative Example is similar to that of the commercially available dressing obtained by needle rolling technology.

Fig. 2 shows the comparison of the coagulation effect between the dressing of Example 3 of the present invention and the dressing of Comparative Example, the rhombus indicates the result of Comparative Example, and the triangle indicates the result of the wound dressing of Example 3. It can be seen from the figure that compared with the dressing of Comparative Example, the dressing of Example 3 has a better blood coagulation effect.

Embodiment 7: animal healing test of compound wound dressing

1. Experimental materials and equipment:

A. the chitosan composite wound dressing obtained by the method of embodiment 3;

B. the chitosan wound dressing that obtains with comparative example method;

c. Rats (wistar rats);

d.Microscope.

2. Experimental method:

a. Apply anesthesia (0.001mL/g) to rats by intramuscular injection, and conduct experiments after they enter deep anesthesia;

b. Use an electric shaver to shave the hair on both sides of the rat, and then use a hair removal cream to remove the hair completely;

c. Disinfect the experimental site with iodine, and perform two 2cm x 2cm wounds on the back of the rat;

d. respectively cover the composite wound dressing obtained by the method of the present invention and the dressing of Comparative Example on the back wound of the rat;

e. Continuously observe the wound healing situation, measure and record. The skin and wound healing process were observed, and digital cameras were used to take pictures to record the adhesion between the dressing and the tissue, the amount of wound fluid secretion, the infection of the tissue around the wound, and the size of the wound.

3. Results:

Table 3 shows the results of macroscopic observation of the wound site and measurement of the wound area using the chitosan composite wound dressing obtained by the method of Example 3 and the chitosan wound dressing obtained by the method of Comparative Example.

Table 3 compares the wound healing situation that obtains dressing with embodiment 3 and comparative example

The dressing experiment results obtained by using Example 3 and Comparative Example are all good in area restoration. The wound using the dressing of the comparative example has almost recovered to a long scab shape in the third week; the wound using the dressing of the embodiment 3 has recovered to a round wound in the third week. The dressing is easy to remove and does not stick to the wound.

Example 8: Cytotoxicity test of composite wound dressing

1. Experimental materials and equipment:

A. the chitosan composite wound dressing obtained by the method of embodiment 3;

b. L929 mouse connective tissue cells;

c. Fluorescent electron microscope (The Olympus FSX100 Bio Imaging Navigator all-in-one microscope).

2. Experimental method:

This test is based on ANSI/AAMI/ISO10993-5:1999 (titled "in vitro toxicity test of medical materials") to evaluate the cytotoxicity (cyctotxicity) of composite wound dressings. Using L929 cells cultured in a culture dish as a negative control group, making L929 mouse cells treated with known cytotoxic phenol as a positive control group, and using only PE membrane as a blank control group to compare with the wound dressing of the present invention experimental group for comparison.

The cells of the negative control group, the blank control group, the positive control group and the experimental group (the chitosan composite wound dressing obtained in Example 3) were collected and stained with trypan blue (trypan blue) and the number of cells in the later stage was counted, the results showed in Table 4. The results in Table 4 show that the number of cells obtained by using the chitosan composite wound dressing of Example 3 is close to the number of the negative control group and the reagent control group, and it will hardly cause the normal mouse fibroblasts to die, so it does not have any Cytotoxicity.

Table 4 Cytotoxicity test results of composite wound dressings

group Average number of cells (cells/mL) negative control group 1.27 x 10 ⁶ Reagent control group 1.3 x 10 ⁶ positive control group 1.67 x 10 ⁴ test group 1.11 x 10 ⁶

Embodiment 9: Composite wound dressing intradermal irritation test

1. Experimental materials and equipment:

A. the chitosan composite wound dressing obtained by the method of embodiment 3;

b. Physiological saline;

c. Male New Zealand white rabbits.

2. Experimental method:

a. Prepare samples according to ANSI/AAMI/ISO10993-12:2007 (titled "Biological Evaluation of Medical Devices-Part 12: Sample Preparation and Reference Materials"). Physiological saline and cottonseed oil are used as the extraction solution, and the extraction ratio is 6cm ² /mL. The test substances were soaked in the extraction solvent in proportion, placed on a shaker with a rotation speed of 100 rpm, and extracted at a temperature of 37°C for 72 hours. In addition, the extraction solvent was treated under the same conditions without the test substance as a blank control;

b. In this experiment, 2 rabbits were used for testing. 18-24 hours before the test, the hair on the back of the rabbit was removed with an electric clipper, with an area of about 15cm x 10cm. Before the test, visually inspect the skin on the back of the test rabbit to ensure that there is no damage;

c. During the test, the test substance physiological saline extract was injected intradermally into 5 parts on the left front side of the back of 2 rabbits. At the same time, the blank control solution was intradermally injected into 5 sites on the left rear side of the test rabbit's back as a control. In the same way, the test substance cottonseed oil extract and the blank control solution were intradermally injected on the right side of the back of the test rabbit. The injection volume for each site is 0.2mL;

d. 24, 48 and 72 hours after the injection, observe according to the intradermal reaction scoring system (as in Table 5), and record the erythema and edema at each injection point of the test site and the control site in Table 6.

Table 5 Scoring system for intradermal reactions

Table 6 Rabbit skin irritation reaction scoring table

From the results in Table 6, it can be seen that the chitosan composite wound dressing obtained according to the method of the present invention has no irritating reaction on animal skin.

Embodiment 10: Composite wound dressing allergy test

1. Experimental materials and equipment:

A. the chitosan composite wound dressing obtained by the method of embodiment 3;

b. Physiological saline;

c. Male guinea pigs.

2. Experimental method:

a. Prepare samples according to ANSI/AAMI/ISO10993-12:2007. Physiological saline was used as the extraction liquid, and the extraction ratio was 3 cm ² /mL. Extraction process The test substance was immersed in the extraction solvent in proportion, placed on a shaker with a rotation speed of 100rpm, and extracted at 37°C for 72 hours. In addition, the extraction solvent was treated under the same conditions without the test substance as a blank control;

b. Before the test, 15 guinea pigs were randomly assigned to the test group and the control group. The test group and the control group respectively use 10 guinea pigs and 5 guinea pigs to test;

c. 18-24 hours before the test, use an electric clipper to shave off the coat of the scapula of all experimental animals, with an area of about 5cm x 7cm. Before the test, visually inspect the skin on the back of the test rabbit to ensure that there is no damage;

d. The day before the test, the prepared extract was injected intradermally at the shaved site on both sides of the shoulder blade of each animal with a volume of 0.1 mL;

e. On the sixth day of the test, the hair of the test site was shaved again, and vaseline containing 10% sodium dodecylsulfonate was applied;

f. On the seventh day of the test, drop 0.5mL of the test substance extract or the blank control solution on a gauze about 2cm x 4cm in size, make it fully absorbed, and apply it to the scapula of the animals in the test group or the control group in a local way. Remove the hairy area and remove the skin patch after 48 hours;

g. After removing the skin patch, observe and score any allergic reactions that may occur at the test site of each animal according to the evaluation criteria in Table 7.

Table 7 Allergy Test (Magnusson-Kligman) Rating Criteria

             

Patch test reaction Score value

             

No visible change 0

Scattered or patchy erythema 1

Moderate and contiguous erythema 2

Severe erythema and edema 3

             

In the detection of 24 hours, 48 hours, and 72 hours after the skin patch was removed, there was no subcutaneous irritation in guinea pigs. That is to say, the chitosan composite wound dressing obtained according to the present invention has no irritation reaction on the animal skin after the allergy test.

The above descriptions are only preferred embodiments of the present invention, and do not limit the present invention in any form. Although the invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. Without departing from the scope of the present invention, those skilled in the art can use the technical contents disclosed above to make some changes or modify them into equivalent embodiments with equivalent changes. Technical Essence Any simple modifications, equivalent changes and modifications made to the above embodiments still fall within the scope of the technical solution of the present invention.

Claims (13)

1. A method for manufacturing a polymer fiber, characterized in that it comprises the following steps: (i) wet-spinning the aqueous spinning stock solution containing natural polymer materials and the spinning forming solution to form wet polymer precursors; (ii) immersing the wet polymer precursor in a softener to obtain a softener-treated wet polymer precursor; (iii) immersing the softener-treated wet polymer precursor in a volatile solvent to remove moisture in the polymer spinning to form polymer fibers. 2. The manufacturing method of the polymer fiber according to claim 1, wherein the natural polymer material is chitosan, alginate or a combination thereof. 3. The method for producing polymer fibers according to claim 1, wherein the aqueous spinning stock solution containing natural polymer materials is a chitosan solution with a concentration of 3 to 10% by weight, and the spinning forming The liquid contains at least a basic compound in a concentration of 3 to 10% by weight. 4. The method for producing polymer fibers according to claim 1, wherein the aqueous spinning stock solution containing natural polymer materials is a sodium alginate solution with a concentration of 3 to 10% by weight, and the spinning forming solution Contains divalent cations at a concentration of 3 to 10% by weight. 5. The method for producing polymer fibers according to claim 1 or 2, wherein the softening agent is a glycerin solution with a concentration of 0.1 to 25% by weight or a polysorbate solution with a concentration of 0.1 to 10% by weight. 6. The method for producing polymer fibers according to claim 1 or 2, wherein the volatile solvent is a lower carbon number alcohol, a lower carbon number ketone or a lower carbon number ether. 7. The method for producing polymer fibers according to claim 5, wherein the volatile solvent is a lower carbon number alcohol, a lower carbon number ketone or a lower carbon number ether. 8. A manufacturing method for a wound dressing, characterized in that it comprises the following steps: (i) obtain polymer fiber according to the method described in claim 1; (ii) forming the polymer fiber into a polymer fiber non-woven fabric; and (iii) treating the non-woven fabric with a natural polymer solution to form a porous coating on the polymer fibers of the non-woven fabric, thereby obtaining a wound dressing. 9. The manufacture method of wound dressing according to claim 8, wherein the step of processing non-woven fabric with natural polymer solution comprises: Spraying the natural polymer solution onto the non-woven fabric to form a non-woven fabric with a porous coating on the polymer fibers; and The nonwoven fabric with the porous coating is dried to obtain a wound dressing. 10. The method for manufacturing a wound dressing according to claim 9, wherein the natural polymer is sprayed onto the non-woven fabric at a spray rate of 10 to 100 milliliters per minute. 11. The method of manufacturing a wound dressing according to claim 9, wherein the drying of the nonwoven fabric with the porous coating is carried out at a temperature of 35 to 85°C. 12. The manufacture method of wound dressing according to claim 8 or 9, wherein said natural polymer solution is selected from the group consisting of sodium alginate, collagen, gelatin, hyaluronic acid, chitosan and derivatives and mixtures thereof composed of groups. 13. A wound dressing, characterized in that it is produced by the method for manufacturing a wound dressing according to any one of claims 8 to 12.

Images